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Brief CommunicationsA potential of autologous pericardium for a sustained-release carrier
of vancomycin: A pilot study in vitro
Akira Marui, MD, PhD,a Keiichi Hirose, MD, PhD,a Hisashi Sakaguchi, MD,a Yoshio Arai, MD, PhD,a
Kazuhiko Doi, MD, PhD,b Masaki Tsukashita, MD,a Takeshi Shimamoto, MD,a Tadashi Ikeda, MD, PhD,a and
Masashi Komeda, MD, PhD,a Kyoto, JapanAutologous pericardium has been widely used to repair des-
tructed annuli in infective endocarditis complicated by annu-
lar abscess.1,2 In the present study we investigated the in
vitro property of autologous pericardium for a sustained-
release carrier of vancomycin.
CLINICAL SUMMARY
Between January and May 2002, autologous pericardium
with pericardial fat was harvested from the patients (n ¼ 6)
who underwent cardiac operations in our institute. After har-
vesting, the pericardium was cut into 7 pieces (1 cm3 1 cm
each). Then 0.2 mL of vancomycin solution (15 mg/mL) was
dropped onto each pericardium and incubated for 1 hour at
room temperature so that the vancomycin solution was com-
pletely absorbed into the pericardium. The 7 pericardial
patches with vancomycin were soaked in 7 test tubes con-
taining 5 mL of saline, respectively. The test tubes were
placed in the shaker and kept at 37C. At 6 hours, 12 hours,
and 1, 3, 5, 7, and 10 days after the incubation, the pericar-
dium and the saline samples were collected and frozen from
1 of the 7 test tubes, and the saline in the residual test tubes
were replaced with 5 mL of fresh saline (ie, the pericardia
were left uncollected), respectively. We replaced the saline
in the residual test tubes at each time point to maintain the
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To prevent the degradation of the samples, we froze them
until the concentrations of vancomycin were measured.
The vancomycin concentrations of the pericardium and the
saline samples were measured as previously described.3,4
We obtained written informed consent from each patient af-
ter a full explanation of this study. The protocol of this study
complied with the principles set forth in the Helsinki Decla-
ration.
All values are expressed as means  standard deviations.
Figure 1 shows that the percentage reaming of vancomycin
in the pericardium at each time point was 67.8%  17.8%,
53.8% 12.3%, 37.8% 9.8%, 25.1% 10.1%, 12.6%
 3.3%, 7.1%  3.1%, and 4.3%  1.7% for 6 hours,
12 hours, and 1, 3, 5, 7, and 10 days after the incubation,
respectively. Figure 2 shows that the concentrations of
vancomycin in the saline samples were 789  143 mg/mL,
376  56 mg/mL, 144  23 mg/mL, 56  14 mg/mL, 38 
5.2 mg/mL, 27  3.8 mg/mL, and 15  2.7 mg/mL for
6 hours, 12 hours, and 1, 3, 5, 7, and 10 days after the incu-
bation, which were all greater than the minimum inhibitory
concentration of vancomycin (2.0 mg/mL) against methicil-
lin-resistant Staphylococcus aureus (MRSA). These results
indicate that the pericardium can slowly release vancomycin
and maintain the minimum inhibitory concentration of
MRSA around the pericardium for more than 10 days.
DISCUSSION
In the present study we found that the autologous pericar-
dium with fat might have a potential for a sustained-release
carrier of vancomycin. Although this is an in vitro study and
the mechanism of the sustained release was unclear, the
property might help prevent prosthetic valve endocarditis
by MRSA after reconstruction of the infected annulus.
Antibiotics are usually administrated systematically to
prevent all forms of infection; however, this might beardiovascular Surgery c Volume 137, Number 3 783
Brief Communicationsinsufficient to treat prosthetic valve endocarditis because the
prosthesis directly contacts the infective sites.1,2 Further-
more, maintenance of a sufficient blood concentration of
antibiotics is sometimes difficult because prolonged syste-
mic administration of high-dose antibiotics induces serious
organ damage.
To avoid such disadvantages, we developed a local sus-
tained-release system of vancomycin by using a poly-L-lac-
tide-co-caprolactone sheet.3,4 This sustained-release sheet of
vancomycin drastically reduced the number of MRSA cells
and prevented graft infection of the subcutis3 and the ab-
dominal aorta.4 However, the fragile poly-L-lactide-co-
caprolactone sheet cannot tolerate surgical manipulation
and might cause thromboembolism if used in the cardiac
cavity. On the other hand, autologous pericardium can be
applied in several situations of cardiothoracic surgery, in-
cluding annular reconstruction, and can be advantageous
in terms of biocompatibility. However, it is difficult to
know from the present data whether the same pericardial
concentrations are maintained under more physiologic con-
ditions. Thus further studies by large animals are required to
determine the efficacy in vivo.
Fibrin glue has been applied as a carrier for vancomycin5;
however, it can also cause serious thromboembolism. In
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FIGURE 1. Release profile of vancomycin from the pericardium.784 The Journal of Thoracic and Cardiovascular Suraddition, fibrin glue cannot release antibiotics for a sufficient
period and the property of sustained release of vancomycin
from the fibrin glue was not satisfactory compared with
those of other antibiotics, such as teicoplanin and gentami-
cin.5 We did not use glutaraldehyde for the preparation of
pericardium to maintain its antibacterial and sustained-
release properties.
In conclusion, autologous pericardium might have a po-
tential for a sustained-release carrier of vancomycin. Further
studies are required to determine the efficacy in vivo.
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FIGURE 2. Concentration of vancomycin in the saline samples. MIC,
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